Fluticasone Propionate And Salmeterol Powder
Product Images NDC 71205-262

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 71205-262). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Propionate Chemical Structure (Fp Sal Spl Graphic 01)

Chemical structure of the active ingredients fluticasone propionate and salmeterol. The diagram shows the molecular arrangement typical for these compounds used in respiratory inhalation powder formulations.*

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Fp Sal Spl Graphic 02)

Chemical structure diagram depicting two molecules related to fluticasone propionate and salmeterol, active ingredients in Fluticasone Propionate and Salmeterol DISKUS inhalation powder.*

FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 03)

A line graph displaying the percentage change in FEV1 over 12 weeks plus an endpoint for four treatment groups: Fluticasone propionate/salmeterol 100/50 mcg twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The graph shows increasing trends in lung function improvement, with the combination therapy group showing the highest percentage change compared to others.*

FDA Label Image

Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 04)

A line graph depicting the percent change in FEV1 over 12 hours starting from baseline on Day 1. It compares four groups: fluticasone propionate/salmeterol 100/50 mcg twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. The y-axis shows percent change in FEV1, and the x-axis shows time in hours.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 05)

This line graph depicts the percentage change in FEV1 (forced expiratory volume in 1 second) relative to Day 1 baseline over a 12-hour period. Four groups are compared: Fluticasone propionate/salmeterol 100/50 mcg twice daily, salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. The graph shows FEV1 percentage changes measured hourly, illustrating the effect of these treatments on lung function over time.*

FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 06)

A line graph depicting the percentage change in FEV1 over 24 weeks for three groups: Fluticasone propionate/salmeterol 250/50 mcg twice daily, Salmeterol 50 mcg twice daily, and Placebo. The graph includes data points and baseline FEV1 values, showing greater improvement for the combination therapy versus Salmeterol alone and Placebo.*

FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 07)

A line graph comparing percent change in FEV1 over 24 weeks among three groups: fluticasone propionate/salmeterol 250/50 mcg, fluticasone propionate 250 mcg, and placebo. The graph shows data points over days and weeks with sample sizes listed for each group at various intervals.*

FDA Label Image

Figure A (Fp Sal Spl Graphic 08)

An illustrated diagram of a Fluticasone Propionate and Salmeterol DISKUS inhalation device showing labeled parts including the Outer Case, Mouthpiece, Lever, Thumb Grip, and Counter. The label on the device indicates it holds 60 blisters of Fluticasone Propionate/Salmeterol DISKUS Powder 100/50 mcg.*

FDA Label Image

Figure B (Fp Sal Spl Graphic 09)

An instructional illustration showing hands holding a Fluticasone Propionate and Salmeterol DISKUS inhaler device. The image demonstrates the action of sliding the inhaler lever to the right, indicated by a large white arrow, which is part of preparing the device for use.*

FDA Label Image

Figure C (Fp Sal Spl Graphic 10)

An instructional image showing a person holding a Fluticasone Propionate and Salmeterol DISKUS inhaler. The image highlights the proper hand grip and depicts an arrow indicating the direction to slide the inhaler open before use.*

FDA Label Image

Ifu Figure D (Fp Sal Spl Graphic 11)

Illustration showing a woman demonstrating how to use a Fluticasone Propionate and Salmeterol DISKUS inhaler. She is holding the DISKUS device near her mouth, positioned for inhalation, indicating its use for respiratory administration of the medication powder.*

FDA Label Image

Figure E (Fp Sal Spl Graphic 12)

Black and white illustration of a woman using a Fluticasone Propionate and Salmeterol DISKUS inhaler by placing the device mouthpiece in her mouth, demonstrating the inhalation process for respiratory powder medication.*

FDA Label Image

Figure F (Fp Sal Spl Graphic 13)

An instructional illustration showing hands holding a Fluticasone Propionate and Salmeterol DISKUS inhaler. The image includes an arrow indicating a sliding motion to operate the device, likely to prepare the inhaler for use.*

FDA Label Image

Ifu Figure G (Fp Sal Spl Graphic 14)

An instructional illustration showing a woman looking at a glass of water placed on a table beside a hand-operated device dispensing a liquid into a sink or drain. The scene suggests a step or precaution related to medication or inhalation product use involving water and disposal.*

FDA Label Image

Figure H (Fp Sal Spl Graphic 15)

Fluticasone Propionate and Salmeterol DISKUS inhalation powder device labeled with strength 100/50 mcg. The black, oval-shaped inhaler holds 60 blisters of powder for respiratory inhalation. The label prominently displays the dosage strength and active ingredients. An extendable mouthpiece with a number 5 is shown extended from the device.*

FDA Label Image

71205-262-60 (Fp Sal Spl Graphic 17)

Label for Fluticasone Propionate 250 mcg / Salmeterol 50 mcg Inhalation Powder, 60 count, relabeled by Proficient Rx LP. The label includes dosage strengths, instructions for oral inhalation only, and product identification details such as NDC 71205-262-60 and manufacturer GlaxoSmithKline Research. It also features storage instructions and safety warnings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.